High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis

Basta, Giuseppina; Castagnini, Marta; Turco, Serena Del; Epistolato, Maria Carmela; Righini, Paolo; Sangiorgi, Giuseppe; Caterina, Raffaele De; Tanganelli, Piero

doi:10.1111/j.1365-2362.2009.02212.x

Cited by 19 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Here, we expand these explorations to the relationships between sRAGE and carotid IMT and plaque. Prior studies have demonstrated a relationship between total sRAGE or esRAGE and carotid IMT (10;21), but very limited data exists between sRAGE levels and carotid plaque (22). In the current study we did not see any relationship with carotid IMT or plaque presence.…”

Section: Discussionmentioning

confidence: 99%

Serum soluble RAGE levels and carotid atherosclerosis: The Northern Manhattan Study (NOMAS)

et al. 2015

View full text Add to dashboard Cite

Background Recent cohort studies suggested that serum levels of soluble Receptor for Advanced Glycation End-products (sRAGE) are associated with the risk of cardiovascular disease. We hypothesized that sRAGE levels are associated with subclinical atherosclerosis in a racially and ethnically diverse population. Methods and results 828 stroke-free participants from the Northern Manhattan Study (mean age 71.1±8.7yrs; 64% Hispanic, 19% black, and 17% white) underwent high-resolution carotid B-mode ultrasound to measure carotid plaque (present in 62% of subjects) and intima-media thickness (IMT) (mean Total= 0.96±0.10 mm). Serum sRAGE was measured by ELISA and associations tested between sRAGE with IMT and plaque presence. Soluble RAGE levels were not associated with plaque presence or IMT after adjusting for sociodemographic, vascular risk factors and medication use. Stratification by race-ethnicity did not reveal any associations with carotid IMT or plaque. Conclusion In the present study, sRAGE levels were not associated with carotid atherosclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum soluble RAGE levels and carotid atherosclerosis: The Northern Manhattan Study (NOMAS)

et al. 2015

View full text Add to dashboard Cite

show abstract

“…One is that high plasma glucose may heighten blood viscosity and quicken the conduction of PWV [9]. Another is that high plasma glucose can quicken the course of atherosclerosis because high plasma can raise the content of advanced glycation endproducts [10].…”

Section: Univariate Correlation Between Bapwv and Selected Clinical Vmentioning

confidence: 99%

Associated Factors of Brachial‐Ankle Pulse Wave Velocity in Hypertensive Patients Aged 80 and Over

Bian

Pan

et al. 2012

CNS Neuroscience & Therapeutics

View full text Add to dashboard Cite

“…Plasma CML and sRAGE levels were elevated after percutaneous coronary interventions with stenting, and positively associated with the extent of vascular injury (80). Further, Basta et al reported that plasma sRAGE levels were higher in non-diabetic patients with symptomatic carotid atherosclerosis than those without symptom (81). They also showed that in symptomatic patients, plasma levels of sRAGE were positively associated with CML, and CML and RAGE levels in carotid plaques were correlated with each other (81).…”

Section: Srage and Cvdmentioning

confidence: 99%

Soluble form of a receptor for advanced glycation end products sRAGE as a biomarker

Yamagishi

Matsui²

2010

Front Biosci

123

View full text Add to dashboard Cite

There is a growing body of evidence that advanced glycation end products (AGEs) and their receptor (RAGE) system are implicated in various disorders, including vascular complications in diabetes, cardiovascular disease, neurodegenerative diseases, inflammatory and autoimmune disorders, and cancer growth and metastasis. Indeed, the engagement of RAGE with AGEs elicits oxidative stress generation and evokes inflammatory and thrombogenic responses, thus playing an important role in these devastating disorders. Moreover, since administration of a recombinant soluble form of RAGE (sRAGE), has been shown to block the AGE-RAGE signaling pathway in animal models, exogenously administered sRAGE may capture and eliminate circulating AGEs, thus protecting against the AGE-elicited tissue damage by acting as a decoy receptor for AGEs. Recently, sRAGE has been identified in humans. However, there are a few comprehensive papers about the regulation and role of sRAGE in humans. Therefore, in this paper, we review the kinetics, regulation and pathophysiological role of sRAGE in humans. We further discuss the potential clinical utility of measuring sRAGE in various disorders as a biomarker.

show abstract

High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis

Abstract: Plasma levels of sRAGE are higher in symptomatic than asymptomatic carotid atherosclerosis. Higher levels of sRAGE in symptomatic patients may be markers of a higher degree of vascular inflammation in such patients.

Cited by 19 publications

References 31 publications

Serum soluble RAGE levels and carotid atherosclerosis: The Northern Manhattan Study (NOMAS)

Serum soluble RAGE levels and carotid atherosclerosis: The Northern Manhattan Study (NOMAS)

Associated Factors of Brachial‐Ankle Pulse Wave Velocity in Hypertensive Patients Aged 80 and Over

Soluble form of a receptor for advanced glycation end products sRAGE as a biomarker

Contact Info

Product

Resources

About